Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD

NCT ID: NCT07014111

Last Updated: 2025-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-02

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease on Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fight Fatigue

Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages

Group Type EXPERIMENTAL

Fight Fatigue

Intervention Type BEHAVIORAL

Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.

Attention Control

End-stage kidney disease education, followed by text messages (over 12 weeks)

Group Type ACTIVE_COMPARATOR

Attention Control

Intervention Type OTHER

End-stage kidney disease education

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fight Fatigue

Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.

Intervention Type BEHAVIORAL

Attention Control

End-stage kidney disease education

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months
* Can read and speak English
* Fatigue measured via visual analogue scale, score ≥4 over the last week
* Able to stand and walk one block
* Has a cell phone that can receive text messages

Exclusion Criteria

* Patient's nephrologist refuses for them to participate
* Unstable angina
* Unstable pulmonary disease or pulmonary symptoms that preclude participation
* Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles-
* Cognitive impairment that, in the judgement of the research team, precludes trial participation
* Participation in the formative phase of the development of Fight Fatigue
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role collaborator

University of Illinois at Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mary Hannan

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UI Health/University of Illinois Chicago

Chicago, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mary Hannan, PhD

Role: CONTACT

3123554838

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mary Hannan

Role: primary

312-355-4838

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R34AT012770

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY2025-0281

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Light Therapy in End Stage Kidney Disease
NCT06310161 NOT_YET_RECRUITING NA
Resistance Exercise in Hemodialysis Patients
NCT06604221 NOT_YET_RECRUITING NA